Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome

Lancet. 2003 Aug 9;362(9382):449-50. doi: 10.1016/s0140-6736(03)14072-x.

Abstract

In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ambulatory Care
  • Cytokines / adverse effects
  • Cytokines / immunology
  • Female
  • Humans
  • Male
  • Meningitis, Meningococcal / immunology
  • Meningitis, Meningococcal / prevention & control*
  • Meningococcal Vaccines / adverse effects*
  • Meningococcal Vaccines / therapeutic use*
  • Nephrotic Syndrome / drug therapy
  • Nephrotic Syndrome / etiology*
  • Nephrotic Syndrome / immunology*
  • Recurrence
  • Risk Factors
  • Vaccination / adverse effects*

Substances

  • Cytokines
  • Meningococcal Vaccines
  • serogroup C meningococcal conjugate vaccine